Daniel Gusenleitner
Daniel Gusenleitner
Novartis Institutes for Biomedical Research
Verified email at novartis.com
Title
Cited by
Cited by
Year
Targetable genetic features of primary testicular and primary central nervous system lymphomas
B Chapuy, MGM Roemer, C Stewart, Y Tan, RP Abo, L Zhang, AJ Dunford, ...
Blood, The Journal of the American Society of Hematology 127 (7), 869-881, 2016
3212016
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
SJ Rodig, D Gusenleitner, DG Jackson, E Gjini, A Giobbie-Hurder, C Jin, ...
Science translational medicine 10 (450), 2018
1892018
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma
CD Carey, D Gusenleitner, M Lipschitz, MGM Roemer, EC Stack, E Gjini, ...
Blood 130 (22), 2420-2430, 2017
1582017
GeneSigDB: a manually curated database and resource for analysis of gene expression signatures
AC Culhane, MS Schröder, R Sultana, SC Picard, EN Martinelli, C Kelly, ...
Nucleic acids research 40 (D1), D1060-D1066, 2012
1252012
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
PB Subrahmanyam, Z Dong, D Gusenleitner, A Giobbie-Hurder, ...
Journal for immunotherapy of cancer 6 (1), 1-14, 2018
902018
An aryl hydrocarbon receptor-mediated amplification loop that enforces cell migration in ER−/PR−/Her2− human breast cancer cells
O Novikov, Z Wang, EA Stanford, AJ Parks, A Ramirez-Cardenas, ...
Molecular pharmacology 90 (5), 674-688, 2016
772016
Cancer-germline antigen expression discriminates clinical outcome to CTLA-4 blockade
SA Shukla, P Bachireddy, B Schilling, C Galonska, Q Zhan, C Bango, ...
Cell 173 (3), 624-633. e8, 2018
662018
Genomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of action
D Gusenleitner, SS Auerbach, T Melia, HF Gómez, DH Sherr, S Monti
PLoS One 9 (7), e102579, 2014
562014
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease
B Chapuy, H Cheng, A Watahiki, MD Ducar, Y Tan, L Chen, MGM Roemer, ...
Blood, The Journal of the American Society of Hematology 127 (18), 2203-2213, 2016
552016
iBBiG: iterative binary bi-clustering of gene sets
D Gusenleitner, EA Howe, S Bentink, J Quackenbush, AC Culhane
Bioinformatics 28 (19), 2484-2492, 2012
392012
ASSIGN: context-specific genomic profiling of multiple heterogeneous biological pathways
Y Shen, M Rahman, SR Piccolo, D Gusenleitner, NN El-Chaar, L Cheng, ...
Bioinformatics 31 (11), 1745-1753, 2015
372015
RamiGO: an R/Bioconductor package providing an AmiGO visualize interface
MS Schröder, D Gusenleitner, J Quackenbush, AC Culhane, ...
Bioinformatics 29 (5), 666-668, 2013
362013
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised …
R Dummer, JC Brase, J Garrett, CD Campbell, E Gasal, M Squires, ...
The Lancet Oncology 21 (3), 358-372, 2020
332020
Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens
CD Carey, D Gusenleitner, B Chapuy, AE Kovach, MJ Kluk, HH Sun, ...
The Journal of Molecular Diagnostics 17 (1), 19-30, 2015
222015
GCOD-GeneChip Oncology Database
F Liu, J White, C Antonescu, J Quackenbush
BMC bioinformatics 12 (1), 46, 2011
192011
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
R Dummer, C Lebbé, V Atkinson, M Mandalà, PD Nathan, A Arance, ...
Nature Medicine 26 (10), 1557-1563, 2020
102020
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma
GK Griffin, JL Weirather, MGM Roemer, M Lipschitz, A Kelley, PH Chen, ...
Blood, The Journal of the American Society of Hematology 137 (10), 1353-1364, 2021
62021
Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities
EA Morgan, MP Sweeney, T Tomoka, N Kopp, D Gusenleitner, RA Redd, ...
Blood advances 1 (1), 84-92, 2016
52016
Actionable genetic features of primary testicular and primary central nervous system lymphomas
B Chapuy, MGM Roemer, Y Tan, C Stewart, L Zhang, AJ Dunford, ...
Blood, The Journal of the American Society of Hematology 124 (21), 74-74, 2014
42014
Effect of first-line spartalizumab+ dabrafenib+ trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF …
R Dummer, K Biette, D Gusenleitner, R Ramesh, C Lebbe, V Atkinson, ...
Journal of Clinical Oncology 38 (15_suppl), 10034-10034, 2020
22020
The system can't perform the operation now. Try again later.
Articles 1–20